By combining bioinformatics analysis and experimental validation, this work highlights PDE3B and HBB as potential prognostic biomarkers and therapeutic targets for breast cancer, providing a deeper understanding of the molecular mechanisms underlying tumor heterogeneity and progression. Here, PDE3B is linked to breast carcinoma.